[go: up one dir, main page]

WO2001073060A3 - 18221, nouveau phosphatase a specificite double et ses utilisations - Google Patents

18221, nouveau phosphatase a specificite double et ses utilisations Download PDF

Info

Publication number
WO2001073060A3
WO2001073060A3 PCT/US2001/009603 US0109603W WO0173060A3 WO 2001073060 A3 WO2001073060 A3 WO 2001073060A3 US 0109603 W US0109603 W US 0109603W WO 0173060 A3 WO0173060 A3 WO 0173060A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
methods
expression vectors
dual specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/009603
Other languages
English (en)
Other versions
WO2001073060A9 (fr
WO2001073060A2 (fr
Inventor
Rachel A Meyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU2001247782A priority Critical patent/AU2001247782A1/en
Priority to EP01920760A priority patent/EP1268818A2/fr
Publication of WO2001073060A2 publication Critical patent/WO2001073060A2/fr
Publication of WO2001073060A3 publication Critical patent/WO2001073060A3/fr
Anticipated expiration legal-status Critical
Publication of WO2001073060A9 publication Critical patent/WO2001073060A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des molécules d'acides nucléiques isolées, appelées molécules d'acides nucléiques 18221, qui codent de nouveaux membres de la famille des phosphatase à spécificité double. En outre, cette invention concerne des molécules d'acides nucléiques antisens, des vecteurs d'expression recombinés contenant ces molécules d'acides nucléiques 18221, des cellules hôtes dans lesquels on a introduit les vecteurs d'expression, et des animaux transgéniques dans lesquels on a introduit ou disloqué un gène 18221. De plus, cette invention concerne des protéines 18221 isolées, des protéines de fusion, des peptides antigéniques et des anticorps anti-18221. Cette invention concerne également des méthodes diagnostiques utilisant ces compositions, ainsi que des procédés de modulation de la différentiation et de la prolifération des cellules hématopoïétiques (par exemple des cellules érythrocytes) au moyen des compositions de cette invention. De même, cette invention concerne des méthodes de traitement, de prévention et/ou de diagnostic des troubles hématopoïétiques.
PCT/US2001/009603 2000-03-24 2001-03-22 18221, nouveau phosphatase a specificite double et ses utilisations Ceased WO2001073060A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001247782A AU2001247782A1 (en) 2000-03-24 2001-03-22 18221, dual specificity phosphatase and uses thereof
EP01920760A EP1268818A2 (fr) 2000-03-24 2001-03-22 18221, nouveau phosphatase a specificite double et ses utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19185800P 2000-03-24 2000-03-24
US60/191,858 2000-03-24

Publications (3)

Publication Number Publication Date
WO2001073060A2 WO2001073060A2 (fr) 2001-10-04
WO2001073060A3 true WO2001073060A3 (fr) 2002-04-04
WO2001073060A9 WO2001073060A9 (fr) 2002-12-19

Family

ID=22707181

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/009603 Ceased WO2001073060A2 (fr) 2000-03-24 2001-03-22 18221, nouveau phosphatase a specificite double et ses utilisations
PCT/US2001/009477 Ceased WO2001073059A2 (fr) 2000-03-24 2001-03-23 38692 et 21117, nouvelles molecules de phosphatase a double specificite et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009477 Ceased WO2001073059A2 (fr) 2000-03-24 2001-03-23 38692 et 21117, nouvelles molecules de phosphatase a double specificite et leurs utilisations

Country Status (4)

Country Link
US (2) US20020065406A1 (fr)
EP (2) EP1268818A2 (fr)
AU (2) AU2001247782A1 (fr)
WO (2) WO2001073060A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479270B1 (en) * 2000-02-14 2002-11-12 Pe Corporation (Ny) Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
US20020137170A1 (en) * 2000-09-26 2002-09-26 Ceptyr, Inc. DSP-16 dual-specificity phosphatase
DE10056802B4 (de) * 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
IL155653A0 (en) * 2000-12-20 2003-11-23 Bristol Myers Squibb Co Polynucleotides encoding human phosphatases
WO2004028554A2 (fr) * 2002-09-27 2004-04-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines skrp, astray, string, vacm associees a la regulation metabolique
BRPI0510132A (pt) 2004-04-22 2007-10-02 Commw Scient Ind Res Org sìntese de ácidos graxos poliinsaturados de cadeia longa por células recombinantes
DK1756280T3 (en) * 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
EP2290074B1 (fr) 2004-05-28 2014-12-17 Asuragen, Inc. Procédés et compositions impliquant du microARN
WO2008073922A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Fonctions et cibles de microarn let-7
CA2857879A1 (fr) 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
BRPI0716075A2 (pt) 2006-08-29 2013-08-06 Commw Scient Ind Res Org sÍntese de Ácidos graxos
WO2008036776A2 (fr) * 2006-09-19 2008-03-27 Asuragen, Inc. Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
EP2487240B1 (fr) * 2006-09-19 2016-11-16 Interpace Diagnostics, LLC Micro ARN différemment exprimés dans des maladies pancréatiques et leurs utilisations
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN101801419A (zh) * 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
EP2198050A1 (fr) 2007-09-14 2010-06-23 Asuragen, INC. Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009100430A2 (fr) * 2008-02-08 2009-08-13 Asuragen, Inc Micro arn (mirna) exprimés différentiellement dans des nœuds lymphoïdes prélevés chez des patients atteints d’un cancer
EP2268832A2 (fr) * 2008-03-06 2011-01-05 Asuragen, INC. Marqueurs microrna pour la récurrence d un cancer colorectal
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
EP2285960B1 (fr) 2008-05-08 2015-07-08 Asuragen, INC. Compositions et procédés liés à la modulation de miarn-184 de néovascularisation ou d angiogenèse
WO2010056737A2 (fr) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
ES2644883T3 (es) 2008-11-18 2017-11-30 Commonwealth Scientific And Industrial Research Organisation Enzimas y métodos para producir ácidos grasos omega-3
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
PL2861059T3 (pl) 2012-06-15 2017-10-31 Commw Scient Ind Res Org Wytwarzanie długołańcuchowych wielonienasyconych kwasów tłuszczowych w komórkach roślinnych
US9725399B2 (en) 2013-12-18 2017-08-08 Commonwealth Scientific And Industrial Research Organisation Lipid comprising long chain polyunsaturated fatty acids
SG11201610596PA (en) 2014-06-27 2017-01-27 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006245A1 (fr) * 1995-08-04 1997-02-20 Medical Research Council Gene de phosphatase de proteines kinases activees par mitogene (map) et ses utilisations
WO1999002704A2 (fr) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Phosphatase a double specificite et procedes d'utilisation
WO2000060099A1 (fr) * 1999-04-07 2000-10-12 Ceptyr, Inc. Map kinase phosphatase a double specificite dsp-4
WO2001012819A2 (fr) * 1999-08-13 2001-02-22 Sugen, Inc. Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296792A1 (fr) 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
WO2001020004A2 (fr) 1999-09-15 2001-03-22 Incyte Genomics, Inc. Proteines phosphatase et proteines kinase
JP2003517836A (ja) 1999-12-21 2003-06-03 スージェン・インコーポレーテッド 哺乳動物蛋白質ホスファターゼ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006245A1 (fr) * 1995-08-04 1997-02-20 Medical Research Council Gene de phosphatase de proteines kinases activees par mitogene (map) et ses utilisations
WO1999002704A2 (fr) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Phosphatase a double specificite et procedes d'utilisation
WO2000060099A1 (fr) * 1999-04-07 2000-10-12 Ceptyr, Inc. Map kinase phosphatase a double specificite dsp-4
WO2001012819A2 (fr) * 1999-08-13 2001-02-22 Sugen, Inc. Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 10 February 1997 (1997-02-10), M. MARRA ET AL: "The WashU-HHMI Mouse EST project: mu88e05.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone IMAGE:652640 5' similar to TR:G992594 Tyrosine phosphate.;, mRNA sequence", XP002183862 *
DATABASE EMBL 19 June 1998 (1998-06-19), NCI-CGAP: "ow27b10.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:1648027 3' similar to SW:DUS5_human Q16690 Dual Specificity Protein Phosphatase 5; , mRNA sequence", XP002144714 *
DATABASE EMBL 24 June 1998 (1998-06-24), NCI-CGAP: "ow48e06.x1 Soares_parathyroid_tumor_NbHPA omo sapiens clone IMAGE:1650082 3' similar to SW:PTP3_CHLEU Q39491 putative protein tyrosine phosphatase;,mRNA sequence", XP002144713 *
DATABASE EMBL 5 March 1999 (1999-03-05), NCI-CGAP: "tg1109.x1 NCI_CGAP_CLL1 Homo sapiens cDNA clone IMAGE:2108512 3' similar to SW:DUS5_human Q16690 DUAL SPECIFICITY PHOSPHATASE 5; mRNA sequence", XP002183861 *
KEYSE S M: "AN EMERGING FAMILY OF DUAL SPECIFICITY MAP KINASE PHOSPHATASES", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1265, 1995, pages 152 - 160, XP000196716, ISSN: 0167-4889 *
MUDA MARCO ET AL: "Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 272, no. 8, 1997, pages 5141 - 5151, XP002144712, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2001247782A1 (en) 2001-10-08
US20020034807A1 (en) 2002-03-21
WO2001073060A9 (fr) 2002-12-19
WO2001073059A2 (fr) 2001-10-04
US6664089B2 (en) 2003-12-16
WO2001073060A2 (fr) 2001-10-04
AU2001249423A1 (en) 2001-10-08
US20020065406A1 (en) 2002-05-30
EP1268818A2 (fr) 2003-01-02
WO2001073059A3 (fr) 2002-06-20
EP1319078A2 (fr) 2003-06-18

Similar Documents

Publication Publication Date Title
WO2001073060A3 (fr) 18221, nouveau phosphatase a specificite double et ses utilisations
WO2001090325A3 (fr) 50365, un nouveau membre de la famille hexokinase et utilisations
WO2002006302A3 (fr) Nouvelles molecules humaines de phospholipases c, 16816 et 16839, et utilisations correspondantes
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2001064911A3 (fr) 18232, nouvelle phosphatase possedant une double specificite et ses utilisations
WO2001066765A3 (fr) 26583, nouvelle serine/threonine phosphatase et utilisations correspondantes
WO2001064904A3 (fr) Membres de la famille transferase 25324, 50287, 28899, 47007, et 42967 et utilisations de ces derniers
WO2001094563A3 (fr) 46980, nouveau membre de la famille de la neuroligine humaine et utilisations associees
WO2001075076A3 (fr) 33167, nouvelle hydrolase humaine, et utilisations associees
WO2001064905A3 (fr) 2504, 15977 et 14760, nouveaux membres de la famille proteine kinase et leurs utilisations
WO2002006485A3 (fr) 47885, une nouvelle enzyme activant l'ubiquitine humaine et ses applications
WO2001066759A3 (fr) 26886, nouvel element de la famille de la carnitine acyltransferase et ses utilisations
WO2002029042A3 (fr) Molecules 48120, 23479, et 46689, nouvelles hydrolases humaines et leurs applications
WO2001066764A3 (fr) 16835, un nouvel element de la famille c de phospholipase humaine et utilisations correspondantes
WO2002026958A3 (fr) Nouvelle neprilysine protease humaine denommee 56638, et utilisations associees
WO2002016588A3 (fr) A 15985, nouveau membre humain de la famille des proteines kinases serines/threonines, et ses utilisations
WO2002020801A3 (fr) 26199, 33530, 33949, 47148, 50226, et 58764, nouveaux membres de la famille des transferases humaines et utilisations de ceux-ci
WO2001090145A3 (fr) 57805, nouvel element de la famille des cadherines humaines et utilisations correspondantes
WO2003029410A3 (fr) Methodes d'utilisation de 69039, nouveau membre de la famille des echangeurs na/ca humains
WO2002008394A3 (fr) 23430, nouveau membre de la famille des ubiquitines hydrolases de l'homme et ses utilisations
WO2001073051A3 (fr) 46743 et 27417, nouveaux membres de la famille acyltransferase humaine
WO2002010401A3 (fr) 18431 et 32374, elements de la famille des proteine kinases humaines et utilisations correspondantes
WO2002038773A3 (fr) 32544, nouvelle phospholipase c humaine et ses applications
WO2002029037A3 (fr) 57800, nouvelle cadherine humaine et ses applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001920760

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-4/10, 6/10, 7/10 AND 9/10, DRAWINGS, REPLACED BY NEW PAGES 1/10-4/10, 6/10, 7/10 AND 9/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001920760

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP